BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27778144)

  • 1. Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity.
    Bardania H; Shojaosadati SA; Kobarfard F; Dorkoosh F; Zadeh ME; Naraki M; Faizi M
    J Thromb Thrombolysis; 2017 Feb; 43(2):184-193. PubMed ID: 27778144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RGD-Modified Nano-Liposomes Encapsulated Eptifibatide with Proper Hemocompatibility and Cytotoxicity Effect.
    Bardania H; Shojaosadati SA; Kobarfard F; Morshedi D; Aliakbari F; Tahoori MT; Roshani E
    Iran J Biotechnol; 2019 Apr; 17(2):e2008. PubMed ID: 31457055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation.
    Chitkara K; Hogrefe K; Vasa-Nicotera M; Swanson N; Gershlick AH
    J Invasive Cardiol; 2006 Sep; 18(9):417-22. PubMed ID: 16954580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shear-sensitive nanocapsule drug release for site-specific inhibition of occlusive thrombus formation.
    Molloy CP; Yao Y; Kammoun H; Bonnard T; Hoefer T; Alt K; Tovar-Lopez F; Rosengarten G; Ramsland PA; van der Meer AD; van den Berg A; Murphy AJ; Hagemeyer CE; Peter K; Westein E
    J Thromb Haemost; 2017 May; 15(5):972-982. PubMed ID: 28267256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M
    Acta Pol Pharm; 2009; 66(3):235-42. PubMed ID: 19645323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity.
    Cai W; Geng C; Jiang L; Sun J; Chen B; Zhou Y; Yang B; Lu H
    Pharm Dev Technol; 2020 Jun; 25(5):640-648. PubMed ID: 32028816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide.
    Bardania H; Shojaosadati SA; Kobarfard F; Dorkoosh F
    Iran J Biotechnol; 2016 Jun; 14(2):33-40. PubMed ID: 28959324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system.
    Gupta AS; Huang G; Lestini BJ; Sagnella S; Kottke-Marchant K; Marchant RE
    Thromb Haemost; 2005 Jan; 93(1):106-14. PubMed ID: 15630499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
    Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
    Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
    Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
    Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
    J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.
    Lev EI; Hasdai D; Scapa E; Tobar A; Assali A; Lahav J; Battler A; Badimon JJ; Kornowski R
    J Am Coll Cardiol; 2004 Mar; 43(6):966-71. PubMed ID: 15028351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
    Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X
    Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
    Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
    Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effects of eptifibatide and anticoagulants: differences between LMWH and UH or rH in thrombin generation inhibition but not in platelet aggregation inhibition.
    Koestenberger M; Gallistl S; Cvirn G; Roschitz B; Petritsch M; Leschnik B; Muntean W
    Thromb Haemost; 2002 Dec; 88(6):1012-9. PubMed ID: 12529753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of eptifibatide as a bridge antiplatelet agent for intrathecal drug delivery system placement.
    Sisk J; Palma M; Cooper C; Eltahawy E; Atallah J
    Pain Physician; 2012; 15(6):479-83. PubMed ID: 23159964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothermia-induced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrilin).
    Straub A; Azevedo R; Beierlein W; Wendel HP; Scheule AM; Ziemer G
    Thorac Cardiovasc Surg; 2005 Apr; 53(2):80-4. PubMed ID: 15786005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists.
    Thibault G; Tardif P; Lapalme G
    J Pharmacol Exp Ther; 2001 Mar; 296(3):690-6. PubMed ID: 11181894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effect of differentially charged PEGylated lipid-polymer nanoparticles.
    Fuentes E; Yameen B; Bong SJ; Salvador-Morales C; Palomo I; Vilos C
    Nanomedicine; 2017 Apr; 13(3):1089-1094. PubMed ID: 27789259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.